Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2001 December; 2(4): 28–34.
Published online 2015 February 19. doi:  10.1007/BF02830563
PMCID: PMC2784838

Stability of a second-generation cephalosporin veterinary mastitis formulation after electron beam irradiation


This study focused on the chemical stability of the cephalosporin {ie28-1} acid, sodium salt (cephem 1) formulation after electron beam (e-beam) irradiation. The cephem 1 concentrations of samples irradiated at 5, 10, and 15 kilograys for glass vials and low-density polyethylene (LDPE) cannula syringes were not statistically different from the concentrations of the nonirradiated control samples. Samples from each irradiation dose stored in controlled-temperature chambers at 5°C and 30°C for 24 months did not show any concentration changes within statistical limits compared with the nontreated samples. Samples from each irradiation dose stored at 40°C for 12 months also did not show any concentration changes within statistical limits compared with the nontreated samples. The percentage of related substances increased slightly with the increase in ebeam irradiation level and storage temperature, but this increase was within the proposed label claim of 90% to 110% (45–55 mg/g). In conclusion, e-beam sterilization did not affect the chemical stability of cephem 1 intramammary formulation in LDPE cannula syringes, suggesting that e-beam irradiation may be a feasible method for terminal sterilization of this cephem 1 formulation.

Keywords: Cephalosporin, Mastitis, Electron Beam Irradiation, E-beam Irradiation, Chemical Stability

Full Text

The Full Text of this article is available as a PDF (132K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. United States Food and Drug Administration, Irradiation in the Production, Processing and Handling of Food, Federal Register 21 CFR Part 179 page 64108, December 1997.
2. Carlson K, Williams C, Lambert B, Tang F. Guidant Corporations Installation of the SureBeam® On-Site System. Radiation Phys. Chem. 2000;57(3–6):619–623. doi: 10.1016/S0969-806X(99)00505-8. [Cross Ref]
3. Van Lancker M, Herer A, Cleland MR, Jongen Y, Abs M. The on beam application Rhodotron: an industrial high-voltage high-powered electron beam accelerator for polymers radiation processing. Nucl Instrum Methods Phys Res. 1999;151(1–4):242–246. doi: 10.1016/S0168-583X(99)00099-3. [Cross Ref]
4. Li S, Zamansky I, Orlov I, Tyle P, Roy SD. Preformulation studies for the development of a parenteral liquid formulation of an antitumor agent, AG337. PDA J. PharmSciTech. 1997;51(5):181–186. [PubMed]
5. Boess C, Bogl KW. Influence of radiation treatment on pharmaceuticals-a review: alkaloids, morphine derivatives, and antibiotics. Drug Dev Ind Pharm. 1996;22(6):495–529. doi: 10.3109/03639049609108354. [Cross Ref]
6. Jacobs GP. Stability of cefazolin and other new cephalosporins following gamma irradiation. Int J Pharm. 1983;17(1):29–38. doi: 10.1016/0378-5173(83)90015-7. [Cross Ref]
7. Health Canada. Process Validation: Irradiation Sterilization for Pharmaceuticals. Available at: Accessed October, 2001.
8. Stern M. Packaging materials issues in irradiation processing of foods. in Proceedings Polyolefins XII International Conference, Houston, TX,, Society of Plastics Engineers, February 2000.
9. Lencioni E, Travagli V, La Rosa C, Pitotti A, Fuochi PG. Sterilization of pharmaceutical products by accelerated electrons. Boll Chim Farm. 1995;134(3):146–149.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists